Edition:
United Kingdom

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,088.00DKK
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
kr.1,088.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
325,474
52-wk High
kr.1,489.00
52-wk Low
kr.994.80

Chart for

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.27
Market Cap(Mil.): kr.85,016.77
Shares Outstanding(Mil.): 61.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion

* ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB)

23 Jan 2018

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

22 Jan 2018

BRIEF-U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma

* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA

19 Jan 2018

BRIEF-Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights

* GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO

09 Jan 2018

BRIEF-Biotech Genmab sees 2018 expense growth of 40-50 pct

Dec 12 FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA:

12 Dec 2017

Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.

01 Dec 2017

Genmab and J&J 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot.

30 Nov 2017

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

30 Nov 2017

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

30 Nov 2017

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON, Nov 30 Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

30 Nov 2017

Earnings vs. Estimates